# Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

> **NCT03672097** · PHASE4 · COMPLETED · sponsor: **Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company** · enrollment: 204 (actual)

## Conditions studied

- Acute Coronary Syndrome (ACS)

## Interventions

- **DRUG:** Prasugrel

## Key facts

- **NCT ID:** NCT03672097
- **Lead sponsor:** Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-16
- **Primary completion:** 2020-08-19
- **Final completion:** 2020-08-19
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672097, "Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03672097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*